About The Study: In this economic evaluation of extended-release buprenorphine compared with transmucosal buprenorphine for the treatment of opioid use disorder, extended-release buprenorphine was not associated with efficient allocation of limited resources when transmucosal buprenorphine was available. Future initiatives should aim to improve retention rates or decrease costs associated with extended-release buprenorphine.
Authors: Juliet M. Flam-Ross, B.A., of the London School of Hygiene and Tropical Medicine in London, and Sabrina A. Assoumou, M.D., M.P.H., of the Boston Medical Center in Boston, are the corresponding authors.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jamanetworkopen.2023.29583)
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time http://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2023.29583?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=091323
JAMA Network Open